To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Aspirin or Rivaroxaban for Preventing Venous Thromboembolism after Total Knee Arthroplasty

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
December 2022

Aspirin or Rivaroxaban for Preventing Venous Thromboembolism after Total Knee Arthroplasty

Vol: 302| Issue: 4| Number:14| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Aspirin versus Rivaroxaban to Prevent Venous Thromboembolism after Total Knee Arthroplasty: A Double-blinded, Randomized Controlled Trial

Rev Bras Ortop (Sao Paulo) . 2021 Oct 25;57(5):741-746

Contributing Authors:
T Hongnaparak J Janejaturanon K Iamthanaporn P Tanutit V Yuenyongviwat

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Forty patients undergoing total knee arthroplasty for primary knee osteoarthritis were randomized to receive either rivaroxaban (n=20) or Aspirin (acetylsalicylic acid; n=20). Outcomes of interest were hematocrit levels, deep vein thrombosis, and adverse events. Hematocrit levels at 6 and 24 hours, and 2 weeks were similar between the two groups. The incidence of blood transfusion, bleeding, wound...

Join the Conversation

Please Login or Join to leave comments.